# BIONOSTICS

K113764

Quality Solutions

510(k) Summary ) () Submitter's name, address Bionostics, Inc. 7 Jackson Road Devens, MA 01434

Contact Person Randy Byrd VP, Chief Technical Officer (978) 772-7070 x 272

Date of preparation of this summary: 20 December 2011

Device trade or proprietary nam:Gluco Mete-Chec Solution or Inoa

Device common or usual name or classification name:

JJX Single (Specified) Analyte Control, All Types, Assayed and Unassayed

<table><tr><td>REGULATION MEDICAL r SPECIALTY R</td><td>REGULATION NUMBER CLASS</td><td>REGULATION DESCRIPTION</td></tr><tr><td>Chemistry</td><td>862.1660 11</td><td>Glucose Control</td></tr></table>

I. Substantial Equivalence Glucose Meter-Check Control Solution for Infopia is substantially equivalent in function, safety and efficacy to currently marketed devices for the same intended use as shown in the following tables:

<table><tr><td colspan="3">Characteristic Predicate Device</td></tr><tr><td>Name:</td><td>x Infopia Control Solution</td><td>Modified Device Glucose Meter-Check Control</td></tr><tr><td>510(k), Date:</td><td>K0572369, Mar 21 2008</td><td>Solution for Infopia</td></tr><tr><td>Number of levels: Target ranges:</td><td>1, typical fasting glucose</td><td>1, typical fasting glucose 88 - 132 mg/dL</td></tr><tr><td>Analytes:</td><td>94 - 140 mg/dL glucose</td><td>glucose</td></tr><tr><td>Container:</td><td>6 mL LDPE vial with dispensing tip</td><td>6 mL LDPE vial with dispensing tip</td></tr><tr><td>Fill volume:</td><td>and cap</td><td>and cap</td></tr><tr><td>Color: Matrix:</td><td>4 mL red Buffered, aqueous solution of D-</td><td>4 mL red</td></tr></table>

# II. Description of the new device

Glucose Meter-Check Solution for Infopia is a buffered aqueous solution with glucose containing no ingredients of biological origin, or in concentrations qualifying as a controlled product under the Controlled Products Regulation. The Glucose Meter-Check Solution is formulated for optimal performance on Infopia glucose meters using Infopia test strips.

)Intended use of the device

Glucose Meter-Check Solution for Infopia is intended for use to verify the performance and correct operation of Infopia blood glucose monitoring test systems utilizing the Element family of blood glucose test strips. Glucose Meter-Check Solution for Infopia is intended for use by healthcare professionals and people with diabetes mellitus at home.

)Technological characteristcs of the device.

This material consists of viscosity-adjusted, aqueous glucose control solution prepared with a single concentration of D-glucose with recovery on the test systems in the range corresponding to Interval 2 of the glucose contration intervals for evalution of intermediate precision in ISO $1 5 1 9 7 ^ { 2 }$ (96 to $1 4 4 m g / \mathrm { d L } )$ . This solution has been optimized to simulate the response of whole blood on the blood glucose test systems manufactured by Infopia using Infopia blood glucose test strips. The solution contains no hazardous, human or animal derived components.

(Summary of non-clinical tests submitt with the premarket notiication for he devce.

Tests were conducted to verify specific performance requirements:

Closed bottle stability (Shelf-life) b) Stability after opening (Use-life) c) Transport Stability   
d) Test response

Sumy  clinical ts ubmit with th emat oit or h . N/A

(b) (3) Conclusions drawn from the clinical and non-clinical trials. Comparison of technological characteristics, formulation and intended use to predicate devices listed in this summary support the claim of substantial equivalence.

![](images/a4acb25c328caf04536e192057d47aa5f27879b1a75810c47e6a50a600ee4a75.jpg)

<table><tr><td rowspan=1 colspan=1>ProductCode</td><td rowspan=1 colspan=1>Class</td><td rowspan=1 colspan=1>Class Regulation</td><td rowspan=1 colspan=1>Device Name</td><td rowspan=1 colspan=1>DateCreated</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr></table>

Registration and Listing

# Premarket Reviews Completed (None)

# Under Review, Withdrawn or Closed without Product Code (1)

<table><tr><td>13764 calion mm </td><td>GLUCOSE METER-CHECK SOLUTION FOR INFOPIA</td><td>Review &quot; </td><td>TCladao Oliga</td><td></td></tr><tr><td>Image</td><td>FDA.GOV JJK SINGLE ANALYTE CONTROL, ALL TYPES</td><td>.</td><td>2072369</td><td></td></tr><tr><td>K113764 1wup4y</td><td>GLUCOSE METER-CHECK SOLUTION FOR INFOPIA</td><td>Review 4</td><td>Claudio Olga</td><td></td></tr><tr><td>Image</td><td>FDA.GOV JK SINGLE ANALYTE CONTROL, ALL TYPES</td><td></td><td>K103021</td><td>4: 0Te s</td></tr></table>

![](images/dba27259ecb06d5e6ce6466b9d639859fa7b0954d8aa42d927bfcfc3b2f4dddd.jpg)

MDR Summary (None)

MDR Analyst (None)

MDR Distribution by Brand - Death or Injury (None)

Patient Problems (None)

Patient Outcomes (None)

Device Problems (None)

Manufacturer Evaluation Results (None)

Manufacturer Evaluation Conclusions (None)

Recalls (None)

# TPLC disclaimers

We are continuing to improve and enhance the TPLC Universe and the TPLC sheets. When more data is available we will update this message.

Please realize that in this initial release:

Recall data is only available since October, 2009.   
In the Premarket Under Review section and the Recall section, the premarket submission or recall is only included if the product code is specified in CTS. The MDR count is a count of reports and contains duplicate reports.   
MDR track action or additional information letters is not available yet.   
EIR data related to inspections is not yet displayed.   
The TPLC name which consolidates variations on manufacturer names is not yet implemented.   
Publications are not yet linked in.

We are working hard to address these issues and many can be addressed before the next release.

Bionostics, Inc. c/o Randy Byrd Chief Technical Officer 7 Jackson Road Devens, MA 01434

Re: k113764   
Trade/Device Name: Glucose Meter-Check $^ \mathrm { \textregistered }$ Solution for Infopia   
Regulation Number: 21 CFR 862.1660   
Regulation Name: Quality Control Material   
Regulatory Class: Class I, reserved   
Product Code: JJX   
Dated: December 20, 2011   
Received: December 21, 2011

Dear Mr. Byrd:

We have reviewed your Section $5 1 0 ( \mathbf k )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (MA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title , Codeof Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with allthe Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical   
Devices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance...

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm

Sincerely yours,

![](images/6d91fad0a51f86829d21d0d3da4f16897816a0758da3e92c253497e1bf3da7b4.jpg)

Coupney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number:

Device Name: Glucose Meter-CheckÂ® Solution for Infopia

Indications for Use: Glucose Meter-Check Solution for Infopia is intended for use to verify the performance and correct operation of Infopia blood glucose monitoring test systems utilizing Infopia glucose test strips. Glucose Meter-Check Solution for Infopia is intended for use by healthcare professionals and people with diabetes mellitus at home.

For In Vitro Diagnostic Use

Concurrent of CDRH, Office of Device Evaluation (OIVD)

![](images/56b3dbf91da07f64f7894ba74c68c71b5a9531cd41b05857ce78b038724f011b.jpg)

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety